Catherine West – 2016 Parliamentary Question to the Department of Health

The below Parliamentary question was asked by Catherine West on 2016-10-07.

To ask the Secretary of State for Health, when he expects the drug used in HIV PrEP, Truvada to come off patent.

Nicola Blackwood

The National Institute for Health and Care Excellence published a new medicines evidence summary for Truvada for pre-exposure prophylaxis (PrEP) in October 2016. According to this summary, Truvada, compound patents for tenofovir disoproxil and salts expires in July 2017, and tenofovir disoproxil fumarate expires in July 2018. A supplementary protection certificate has also been granted in relation to Truvada which expires in February 2020.